Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

按照协议，礼来公司将启动一项“真实世界”研究，旨在了解替西帕肽（tirzepatide，其Zepbound和Mounjaro药物背后的GLP-1受体激动剂药物）如何影响减肥、糖尿病预防和肥胖相关并发症的预防，以更好地为英国国家卫生服务局（NHS）应对 ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...